The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review
نویسندگان
چکیده
منابع مشابه
Chronic idiopathic urticaria: treatment with omalizumab.
Chronic idiopathic urticaria (CIU) is a common autoimmune skin condition characterized by spontaneously recurring hives for 6 weeks or longer. The new terminology used for CIU in most countries including Canada is chronic spontaneous urticaria (CSU). CSU is associated with significant psychosocial morbidity with a markedly negative impact on overall quality of life. Conventional approaches with...
متن کاملOmalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
BACKGROUND Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients. METHODS In this phase 3, multicenter, ran...
متن کاملOmalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review
OBJECTIVES To examine the evidence derived from randomized controlled clinical trials on the efficacy and safety of omalizumab compared to placebo in controlling symptoms of chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU). DATA SOURCE The electronic databases PubMed, Medline, EMBASE, Biomed Central, The Cochrane Central Register of Controlled Trials (CENTRAL), Wiley, OVID...
متن کاملOmalizumab in the treatment of chronic urticaria.
Omalizumab is a monoclonal anti-immunoglobulin E antibody currently only approved for use in severe, refractory asthma. In recent years, many authors have reported satisfactory results with omalizumab in patients with difficult-to-treat chronic urticaria. As a result, clinical trials were undertaken to broaden the indication of omalizumab to include chronic urticaria, and the drug was recently ...
متن کاملOmalizumab in chronic urticaria: our experience and literature review.
INTRODUCTION Chronic urticaria (CU) severely affects quality of life. If symptoms are not controlled by antihistamines, patients need immunomodulatory drugs. Recent studies show a tremendous effect of omalizumab, a monoclonal antibody against human IgE in refractory CU. METHODS We report on the use of omalizumab in four patients with CU. By reviewing medical files, we estimated the proportion...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American Academy of Dermatology
سال: 2016
ISSN: 0190-9622
DOI: 10.1016/j.jaad.2015.12.052